TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15002680

Group type: EXPERIMENTAL
Intervention: Referral to substance abuse treatment
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Referral to mental health treatment
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Referral to substance abuse and mental health treatment
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Referral rates to substance abuse and mental health treatment
Number of subjects: 400
Study: 11680554

Group type: EXPERIMENTAL
Intervention: Intervention condition (providing instrumental and emotional support and teaching child management skills to mothers)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Existing services comparison condition
Number of subjects: 36
Study: 9504445

Group type: EXPERIMENTAL
Intervention: Multifactorial risk factor intervention
Number of subjects: 508

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 508
Study: 7999931

Group type: EXPERIMENTAL
Intervention: Relevant tones (300 Hz or 6000 Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irrelevant tones (300 Hz or 6000 Hz)
Number of subjects: 0
Study: 3234475

Group type: EXPERIMENTAL
Intervention: Alcoholic oral solution (12 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tablets (12 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Capsules (12 mg)
Number of subjects: 12
Study: 31813531

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1802

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: In-hospital AF
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: Postdischarge AF
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: Postdischarge AF presence vs absence of in-hospital AF
Number of subjects: 1802
Study: 29735974

Group type: EXPERIMENTAL
Intervention: Herbal with acupuncture group (n=32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Herbal group (n=30)
Number of subjects: 62
Study: 28038865

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6 mg administered ∼24 hours after chemotherapy plus bevacizumab every 14 days for 4 cycles, with the option to continue for ≤ 60 months)
Number of subjects: 845

Group type: COMPARATOR
Intervention: Placebo (administered ∼24 hours after chemotherapy plus bevacizumab every 14 days for 4 cycles, with the option to continue for ≤ 60 months)
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 845
Study: 26167714

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for abstinence
Number of subjects: 920

Group type: COMPARATOR
Intervention: Standard care treatment
Number of subjects: 920
Study: 23907740

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg IV over 1 hour q12h for ABSSSI and CABP patients
Number of subjects: 220

Group type: COMPARATOR
Intervention: Ceftaroline fosamil 50-2000 mg IV infusion over 1 hour or IM injection q12h or q24h for healthy subjects
Number of subjects: 220
Study: 21990808

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolytics (IAT)
Number of subjects: 3
Study: 19860230

Group type: COMPARATOR
Intervention: Thiopental (2 mg x kg(‐1)) and Suxamethonium (1.2 mg x kg(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propofol (0.75 mg x kg(‐1)) and Suxamethonium (1.2 mg x kg(‐1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thiopental (2 mg x kg(‐1)) and Vecuronium (0.07 mg x kg(‐1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propofol (0.75 mg x kg(‐1)) and Vecuronium (0.07 mg x kg(‐1))
Number of subjects: 10
Study: 16317061

Group type: EXPERIMENTAL
Intervention: MSH/ACTH(4-10) (0.5 mg) administered intranasally twice daily for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo administered intranasally twice daily for 12 weeks
Number of subjects: 23
Study: 15583914

Group type: EXPERIMENTAL
Intervention: SPECT measurements of dopamine transporter (DAT) using 123I‐beta‐CIT in IPD patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SPECT measurements of dopamine transporter (DAT) using 123I‐beta‐CIT in MSA patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: SPECT measurements of dopamine transporter (DAT) in MSA patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: SPECT measurements of dopamine transporter (DAT) in IPD patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SPECT measurements of dopamine D2-like receptors (D2) using 123I‐epidepride in patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ratio between caudate DAT and D2 binding in IPD patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SPECT measurements of DAT in patients with reduced striatal 123I‐beta‐CIT binding
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SPECT measurements of DAT and D2 receptor binding
Number of subjects: 33
Study: 11323374

Group type: COMPARATOR
Intervention: Awake fiberoptic intubation (AFOI)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (ILMA)
Number of subjects: 38
Study: 9211474

Group type: EXPERIMENTAL
Intervention: 0.5 mg proglumide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg proglumide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05 mg proglumide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 0
Study: 7949999

Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no CHESS)
Number of subjects: 200
Study: 2970220

Group type: EXPERIMENTAL
Intervention: Group 2 physicians received individualized decision analysis; 39% took actions recommended (screening or vaccination).
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Group 1 physicians received general information about vaccine decisions; specific outcome not detailed.
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Group 3 physicians served as controls; specific outcome not detailed.
Number of subjects: 1280
Study: 31736335

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4443
Study: 30017645

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 3 weeks)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 850
Study: 28699558

Group type: EXPERIMENTAL
Intervention: Temephos exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no temephos exposure)
Number of subjects: 0
Study: 25964628

Group type: EXPERIMENTAL
Intervention: Juvéderm Voluma XC
Number of subjects: 235
Study: 24138062

Group type: COMPARATOR
Intervention: Prolonged conservative treatment
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Size of the dural sac
Number of subjects: 142
Study: 16598087

Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA through the medial parapatellar approach
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard instrumentation TKA
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA through the subvastus approach
Number of subjects: 70
Study: 14714360

Group type: EXPERIMENTAL
Intervention: Danshao Granule (DSG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Tripterygium polyglycosides tablet and composite Salviae tablet (Control)
Number of subjects: 63
Study: 9927122

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 60
Study: 7561157

Group type: EXPERIMENTAL
Intervention: 1.6% all‐trans‐retinol (ROL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.025% all‐trans‐retinoic acid (RA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle (70% ethanol/30% propylene glycol)
Number of subjects: 10
Study: 2048660

Group type: COMPARATOR
Intervention: Intravenous diamorphine 0.5 mg/hour as a supplement to extradural bupivacaine (0.125% at 15 ml/hour)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Extradural diamorphine 0.5 mg/hour as a supplement to extradural bupivacaine (0.125% at 15 ml/hour)
Number of subjects: 20
Study: 7272153

Group type: EXPERIMENTAL
Intervention: Atropine 0.6 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.3 mg or 0.2 mg
Number of subjects: 9
Study: 29496604

Group type: EXPERIMENTAL
Intervention: Star labels
Number of subjects: 306

Group type: COMPARATOR
Intervention: Traffic light labels
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Any type of framing (gain, loss, gain + loss)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Framing information
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Label type (star vs. traffic light)
Number of subjects: 306
Study: 28573190

Group type: EXPERIMENTAL
Intervention: Machine perfusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cold storage
Number of subjects: 80
Study: 25774660

Group type: EXPERIMENTAL
Intervention: Health-mentoring intervention
Number of subjects: 182
Study: 24040847

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg b.i.d. for 6 days prior to inhalation of glycopyrronium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glycopyrronium 100 μg inhaled alone
Number of subjects: 20
Study: 21156335

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) plus Bacillus Calmette-Guérin (BCG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG) alone
Number of subjects: 96
Study: 18453021

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 26

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 26
Study: 15681941

Group type: EXPERIMENTAL
Intervention: 5-ml saline injection
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 10-ml saline injection
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 15-ml saline injection
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no saline injection)
Number of subjects: 28
Study: 12851515

Group type: EXPERIMENTAL
Intervention: SPI+ (Isoflavone-rich soy protein isolate)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: SPI- (Isoflavone-poor soy)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Whey control
Number of subjects: 69
Study: 10098816

Group type: EXPERIMENTAL
Intervention: Virtual environment (VE) immersion for 20 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posturographic technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulator sickness symptoms
Number of subjects: 0
Study: 15374159

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 7 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 29
Study: 1817630

Group type: EXPERIMENTAL
Intervention: Magnesium pretreatment with pancuronium (100 micrograms kg‐1)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Priming dose of pancuronium (10 micrograms kg‐1)
Number of subjects: 2
Study: 6127172

Group type: EXPERIMENTAL
Intervention: Acebutolol (1 mg/kg i.v. during the first 2 days followed by a daily oral dose of 600 mg for 3 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (12 untreated subjects)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study: 31145174

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU every 2 weeks for 24 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 30639666

Group type: EXPERIMENTAL
Intervention: Virtual reality enhanced bullying prevention program
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 118
Study: 28385440

Group type: EXPERIMENTAL
Intervention: Implant-retained fixed metal-acrylic resin prostheses
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Implant-supported overdentures
Number of subjects: 22
Study: 26103191

Group type: EXPERIMENTAL
Intervention: Expert Plan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clinical Plan
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PAF Plan
Number of subjects: 10
Study: 24428951

Group type: EXPERIMENTAL
Intervention: Complex breastfeeding support intervention (prenatal/postnatal professional and peer support package continuing till 6 months postpartum)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Complex breastfeeding support intervention
Number of subjects: 443

Group type: COMPARATOR
Intervention: Standard prenatal and postnatal care (Control)
Number of subjects: 443
Study: 22948223

Group type: EXPERIMENTAL
Intervention: 6-month dietary weight loss
Number of subjects: 83
Study: 19447479

Group type: EXPERIMENTAL
Intervention: 12 monthly cycles of paclitaxel (175 mg/m2 over 3 h)
Number of subjects: 296

Group type: COMPARATOR
Intervention: 3 monthly cycles of paclitaxel (175 mg/m2 over 3 h)
Number of subjects: 296
Study: 17293705

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15057546

Group type: EXPERIMENTAL
Intervention: GDM group
Number of subjects: 45
Study: 12368388

Group type: EXPERIMENTAL
Intervention: High vegetable diet
Number of subjects: 37
Study: 9650870

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy plus scaling (group 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Antibiotic therapy (group 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo therapy plus scaling (group 4)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo therapy but no scaling (group 3)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Systemic administration of metronidazole plus amoxicillin
Number of subjects: 16
Study: 7639570

Group type: EXPERIMENTAL
Intervention: 60 MU intravesical alpha‐2b interferon (IFN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 60
Study: 2651328

Group type: EXPERIMENTAL
Intervention: Oral nitroglycerin (0.4 mg) and atenolol (100 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg) and nifedipine (20 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg) and nicardipine (40 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Atenolol (100 mg) alone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral nitroglycerin (0.4 mg)
Number of subjects: 17
Study: 406634

Group type: EXPERIMENTAL
Intervention: Methadone (up to 10 mg)
Number of subjects: 0
Study: 31557537

Group type: EXPERIMENTAL
Intervention: Incremental Step Test (IST)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cardiopulmonary Exercise Testing (CPET)
Number of subjects: 20
Study: 31418258

Group type: EXPERIMENTAL
Intervention: fT4 levels
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: fT3 levels
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: TSH levels
Number of subjects: 49
Study: 28222556

Group type: EXPERIMENTAL
Intervention: Treadmill training with a mass attached on non-paretic lower limb (NPLL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treadmill training only (control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 38
Study: 25939655

Group type: EXPERIMENTAL
Intervention: Heat stress (HS; wearing firefighter personal protective equipment (PPE))
Number of subjects: 12

Group type: COMPARATOR
Intervention: No heat stress (NHS; wearing a cooling shirt and equivalent PPE weight)
Number of subjects: 12
Study: 23650429

Group type: EXPERIMENTAL
Intervention: Unselected young TILs
Number of subjects: 69

Group type: COMPARATOR
Intervention: CD8(+)-enriched TILs
Number of subjects: 69
Study: 21439302

Group type: EXPERIMENTAL
Intervention: Static magnetic field (SMF) exposure using a neodymium-iron-boron magnet, 30-minute exposure interval
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham exposure (control group)
Number of subjects: 18
Study: 18931006

Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide ER (8 mg/day for 4 weeks, 16 mg/day for 6 weeks, 24 mg/day for 6 weeks)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 16514250

Group type: EXPERIMENTAL
Intervention: Intraoperative cytology
Number of subjects: 22

Group type: COMPARATOR
Intervention: Histological examination of permanent sections
Number of subjects: 22
Study: 15485290

Group type: EXPERIMENTAL
Intervention: 12-dose WHO multi-drug therapy (Group 1, 128 patients)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 24-dose WHO multi-drug therapy (Group 2, 85 patients)
Number of subjects: 213
Study: 10932574

Group type: EXPERIMENTAL
Intervention: Public feedback
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Private feedback
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 108
Study: 9174308

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) using propofol with a basal infusion of propofol, n = 20
Number of subjects: 37

Group type: COMPARATOR
Intervention: Neurolept analgesia using an initial bolus dose of fentanyl and droperidol followed by a fentanyl infusion, n = 17
Number of subjects: 37
Study: 1542321

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 4020569

Group type: EXPERIMENTAL
Intervention: Rapid oral rehydration using ORS‐WHO (sodium 90 mmol/L)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Traditional oral fluid replacement (sodium 35 mmol/L)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Rapid return to full feedings appropriate for age
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cholestyramine 2 g four times daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cholestyramine in children with poor initial hydration
Number of subjects: 81
Study: 31294581

Group type: EXPERIMENTAL
Intervention: Sit-stand desks
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study: 29672519

Group type: EXPERIMENTAL
Intervention: Affect labelling condition
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-affect labelling condition (control)
Number of subjects: 110
Study: 26874387

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP), 10 μg/kg, administered subcutaneously twice daily for 12 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25253884

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6',7'-dihydroxybergamottin (DHB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IVIVE approach
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Previous GFJ-drug interaction studies
Number of subjects: 16
Study: 23115989

Group type: EXPERIMENTAL
Intervention: Electrical physical therapy group (ultrashort wave and magnetic therapy instrument, once a day, 5 days for a course of treatment, three cycles)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Western medicine group (beta-aescin 20 mg IV once a day for 5 days, followed by Danshen injection 20 ml IV once a day for 10 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (raised and exercised limb and fingers only)
Number of subjects: 90
Study: 20595697

Group type: EXPERIMENTAL
Intervention: Real acupoint (Liv3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham acupoint
Number of subjects: 10
Study: 18552399

Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SLC6A4 STin2 12/12 carriers
Number of subjects: 90
Study: 15624054

Group type: EXPERIMENTAL
Intervention: Trained group using the laparoscopic camera navigation simulator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with no training
Number of subjects: 20
Study: 12400198

Group type: EXPERIMENTAL
Intervention: Nursing staff directly asking questions about domestic violence during initial assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulus (button) worn by nursing staff in the emergency department
Number of subjects: 0
Study: 10529509

Group type: EXPERIMENTAL
Intervention: wt1 gene expression in newly diagnosed leukemias
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: wt1 gene expression in relapsed leukemias
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Comparison of wt1 expression levels
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Frequency of wt1 expression in acute childhood leukemias
Number of subjects: 61
Study: 7818005

Group type: EXPERIMENTAL
Intervention: Ursodiol 300 mg
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Ursodiol 600 mg
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Ursodiol 1200 mg
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 2150695

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 200 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ipratropium bromide 40 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 micrograms
Number of subjects: 20
Study: 111759

Group type: EXPERIMENTAL
Intervention: Heparin 1 unit/ml of infusate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 80
Study: 6130075

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 31429974

Group type: EXPERIMENTAL
Intervention: 8-week smartphone-based aftercare intervention (German version of 'Recovery Record') with therapist feedback as an adjunct to treatment as usual
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 8-week smartphone-based aftercare intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 40
Study: 29996843

Group type: EXPERIMENTAL
Intervention: β-alanine (BA) 2.4 g/d for 28 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: β-alanine (BA)
Number of subjects: 12